Arcus Ventures

Arcus Ventures is a New York-based private equity firm established in 2007, dedicated to investing in oncology-focused companies. The firm specializes in advanced biopharmaceuticals, leveraging a team of experienced professionals with a profound understanding of the complex oncology market. Their investment thesis centers on identifying and nurturing innovative companies poised to make significant advancements in cancer treatment.

As a private equity investor, Arcus Ventures typically engages in later-stage funding rounds, supporting companies that have demonstrated promising clinical development. Their portfolio includes several notable biopharmaceutical companies that have gone on to achieve significant milestones. This strategic focus allows them to back enterprises with high growth potential within the capital-intensive drug development sector.

Arcus Ventures has a track record of participating in substantial funding rounds, underscoring their capacity for significant capital deployment. For instance, they were an investor in Kura Oncology's Series B financing, which successfully closed at $60 million. Similarly, Arcus Ventures also participated in Mirati Therapeutics' Series C round, which raised $40 million. These examples illustrate their commitment to supporting the growth and development of companies advancing critical oncology therapies, reflecting their role in fostering innovation in the biopharmaceutical landscape.